These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31824468)

  • 1. Multiple Origins and Specific Evolution of CRISPR/Cas9 Systems in Minimal Bacteria (
    Ipoutcha T; Tsarmpopoulos I; Talenton V; Gaspin C; Moisan A; Walker CA; Brownlie J; Blanchard A; Thebault P; Sirand-Pugnet P
    Front Microbiol; 2019; 10():2701. PubMed ID: 31824468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
    Fonfara I; Le Rhun A; Chylinski K; Makarova KS; Lécrivain AL; Bzdrenga J; Koonin EV; Charpentier E
    Nucleic Acids Res; 2014 Feb; 42(4):2577-90. PubMed ID: 24270795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a Type II-A CRISPR-Cas System in
    Mosterd C; Moineau S
    mSphere; 2020 Jun; 5(3):. PubMed ID: 32581075
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative genomics and evolution of trans-activating RNAs in Class 2 CRISPR-Cas systems.
    Faure G; Shmakov SA; Makarova KS; Wolf YI; Crawley AB; Barrangou R; Koonin EV
    RNA Biol; 2019 Apr; 16(4):435-448. PubMed ID: 30103650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactobacillus gasseri CRISPR-Cas9 characterization In Vitro reveals a flexible mode of protospacer-adjacent motif recognition.
    Anderson EM; McClelland S; Maksimova E; Strezoska Ž; Basila M; Briner AE; Barrangou R; Smith AVB
    PLoS One; 2018; 13(2):e0192181. PubMed ID: 29394276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tracrRNA in CRISPR Biology and Technologies.
    Liao C; Beisel CL
    Annu Rev Genet; 2021 Nov; 55():161-181. PubMed ID: 34416117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A newly discovered Bordetella species carries a transcriptionally active CRISPR-Cas with a small Cas9 endonuclease.
    Ivanov YV; Shariat N; Register KB; Linz B; Rivera I; Hu K; Dudley EG; Harvill ET
    BMC Genomics; 2015 Oct; 16():863. PubMed ID: 26502932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
    Kennedy EM; Cullen BR
    Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogrammed tracrRNAs enable repurposing of RNAs as crRNAs and sequence-specific RNA biosensors.
    Liu Y; Pinto F; Wan X; Yang Z; Peng S; Li M; Cooper JM; Xie Z; French CE; Wang B
    Nat Commun; 2022 Apr; 13(1):1937. PubMed ID: 35410423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and Diversity of CRISPR-Cas Systems in the Genus Bifidobacterium.
    Briner AE; Lugli GA; Milani C; Duranti S; Turroni F; Gueimonde M; Margolles A; van Sinderen D; Ventura M; Barrangou R
    PLoS One; 2015; 10(7):e0133661. PubMed ID: 26230606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CRISPR-Cas system - from bacterial immunity to genome engineering.
    Czarnek M; Bereta J
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):901-16. PubMed ID: 27594566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and comparison of CRISPR Loci in Streptococcus thermophilus.
    Hu T; Cui Y; Qu X
    Arch Microbiol; 2020 May; 202(4):695-710. PubMed ID: 31781808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal Targeting by the Type III-A CRISPR-Cas System Can Reshape Genomes in
    Guan J; Wang W; Sun B
    mSphere; 2017; 2(6):. PubMed ID: 29152580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and diversity of tracrRNAs from type II CRISPR-Cas systems.
    Chyou TY; Brown CM
    RNA Biol; 2019 Apr; 16(4):423-434. PubMed ID: 29995560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.